A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures

INTRODUCTION: Patients receiving taxanes are at risk for developing hypersensitivity reactions (HSRs) primarily during first and second lifetime exposures. Immediate HSRs require emergency care and can interfere with the continuation of preferred treatment. Although different approaches to slow titration have been used successfully for desensitization after HSR occurrence, there are no standardized recommendations for taxane titration to prevent HSRs. PURPOSE: To determine if a gradual, three-step infusion rate titration decreases the rate and severity of immediate HSRs during first and second lifetime exposures to paclitaxel and docetaxel. METHODS: We used a prospective, interventional design with historical comparisons to evaluate a sample of 222 first and second lifetime exposure paclitaxel and docetaxel infusions. The intervention was a three-step infusion rate titration provided at the initiation of first and second lifetime exposures. Ninety-nine titrated infusions were compared with 123 historical records of nontitrated infusions. RESULTS: Compared with the nontitrated group (n = 123), the titrated group (n = 99) had significantly less HSRs (19% v 7%; P = .017). No significant difference in HSR severity was found between groups (P = 1.00). However, four nontitrated patients received epinephrine, and one required transfer to the emergency department (ED) because of reaction severity. In contrast, no titrated patients received epinephrine or required transfer to the ED. In the nontitrated group, seven patients did not complete their infusions versus one patient in the titrated group. CONCLUSION: A standardized, three-step infusion rate titration prevented HSR occurrence. Significant issues affecting practice feasibility and sustainability were addressed.

[1]  L. Gilbert,et al.  Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review , 2022, Clinical Reviews in Allergy & Immunology.

[2]  T. Ng,et al.  Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis , 2022, Supportive Care in Cancer.

[3]  Benjamin D. McNeil MRGPRX2 and Adverse Drug Reactions , 2021, Frontiers in Immunology.

[4]  D. Khan,et al.  Non-IgE-Mediated Drug Hypersensitivity Reactions , 2021, Current Allergy and Asthma Reports.

[5]  P. Bonadonna,et al.  Hypersensitivity reactions to chemotherapy: an EAACI Position Paper , 2021, Allergy.

[6]  E. Álvarez-Cuesta,et al.  Medical algorithm: Diagnosis and treatment of hypersensitivity reactions to cancer chemotherapy , 2021, Allergy.

[7]  W. Santimaleeworagun,et al.  Characteristics of immediate hypersensitivity reaction to paclitaxel-based chemotherapy in gynecologic cancer patients. , 2020, Asian Pacific journal of allergy and immunology.

[8]  J. Herrington,et al.  Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[9]  A. Knezevic,et al.  Hypersensitivity Reactions: Priming practice change to reduce incidence in first‐dose rituximab treatment , 2018, Clinical journal of oncology nursing.

[10]  Jiju Antony,et al.  Six Sigma in healthcare: a systematic review of the literature , 2018 .

[11]  M. Picard Management of Hypersensitivity Reactions to Taxanes. , 2017, Immunology and allergy clinics of North America.

[12]  U. Matulonis,et al.  Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. , 2016, The Journal of allergy and clinical immunology.

[13]  M. Castells,et al.  Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review , 2015, Clinical Reviews in Allergy & Immunology.

[14]  G. Wallen Innovations that INSPIRE. , 2014, Nursing management.

[15]  C. Camargo,et al.  Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. , 2014, The journal of allergy and clinical immunology. In practice.

[16]  M. P. Berges-Gimeno,et al.  Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment , 2013, Allergy.

[17]  M. Saif,et al.  Hypersensitivity Reactions to Docetaxel: Retrospective Evaluation and Development of a Desensitization Protocol , 2010, International Archives of Allergy and Immunology.

[18]  U. Matulonis,et al.  Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to chemotherapy : Outcomes and safety of rapid desensitization in 413 cases , 2022 .

[19]  S. Brown Clinical features and severity grading of anaphylaxis. , 2004, The Journal of allergy and clinical immunology.

[20]  M. Allwood,et al.  The extraction of diethylhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection , 1996 .

[21]  E. Eisenhauer,et al.  Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  L. Grochow,et al.  Phase I trial of taxol in patients with advanced cancer. , 1987, Cancer treatment reports.